Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | FABP6 | P51161 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 5/20 | 0.34 |
| ▸ | GRM5 | P41594 | 3/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1805517 | 1.00 | MAOB (0.36) | MAOBMAOAFABP6METGRM5 | |
| SCHEMBL1805518 | 1.00 | MAOB (0.36) | MAOBMAOAFABP6METGRM5 | |
| SCHEMBL1807031 | 0.83 | FABP6 (0.34) | MAOBMAOAFABP6MET | |
| SCHEMBL1807033 | 0.83 | FABP6 (0.34) | MAOBMAOAFABP6MET | |
| SCHEMBL1807030 | 0.83 | FABP6 (0.34) | MAOBMAOAFABP6MET | |
| SCHEMBL2598951 | 0.81 | PBRM1 (0.36) | METGSK3BNPC1ALDH1A1HPGD | |
| SCHEMBL860468 | 0.81 | PBRM1 (0.36) | METGSK3BNPC1ALDH1A1HPGD | |
| SCHEMBL2598948 | 0.81 | PBRM1 (0.36) | METGSK3BNPC1ALDH1A1HPGD | |
| SCHEMBL860469 | 0.81 | PBRM1 (0.36) | METGSK3BNPC1ALDH1A1HPGD | |
| SCHEMBL1805676 | 0.81 | MAOA (0.34) | MAOBMAOAFABP6METGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571353-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2017-08-09 | — | — | EP | disclosed |
| US-8846951-B2 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC. (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2571353-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | AbbVie Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| WO-2011146089-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20110118231-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118231-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR3A, HTR5A, HTR3C | MAOB 56/4885MAOA 67/4885FABP6 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.